Technical Efficacy of a Direction Specific Radiofrequency Device in the Performance of Lumbar Medial Branch Neurotomies
NCT ID: NCT02120625
Last Updated: 2017-04-28
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
8 participants
OBSERVATIONAL
2013-12-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves for theTreatment of Lumbar Facet Syndrome
NCT02478437
Technical Description of Cooled Radiofrequency Ablation of Lumbar Medial Branches for the Treatment of Lumbar Facet Pain
NCT01590004
PNS vs RFA for Facet Joint Pain
NCT05952518
Radiofrequency Nerve Ablation Versus Sham to Treat Chronic Low Back Pain Caused by Sacroiliac Joint Dysfunction
NCT01104051
Evaluation of Multi-Tined Expandable Electrode (MEE) Efficacy and Safety in Treatment of Lumbar Facet Arthropathy by Radiofrequency Neurotomies Compared to Conservative Medical Management.
NCT04730700
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. Initial evaluation with physician and study eligibility determination
2. Presentation of study to patient and informed consent obtained
3. Baseline paraspinous muscle EMG performed
4. MB (medial branch)/DR (dorsal ramus) radiofrequency neurotomy with Nimbus MEE probe (start date)
5. Post-operative soreness managed with oral and topical medications and possibly 1-4 physical therapy sessions, as needed
6. MD visit at intake evaluation and at 3 and 6 weeks following the procedure.
7. Paraspinal needle electromyography, using the mini-paraspinal mapping ("miniPM") technique of Haig will be carried out at baseline (pre-procedure) and between 3 and 6 weeks post-procedure.
8. MRI, with sequencing which allows for volumetric calculations (see Appendix III), will be obtained on all of the ten chosen subjects at 7 days post-procedure. If there is any evidence of edema or coagulation changes with volume of greater than 600 cubic mm, or evidence of bony edema or other changes believed to be due to the procedure, then a follow up MRI will be obtained at 14 days post-procedure. If bony edema changes are present at 14 days, repeat MRI will be obtained at 6 weeks post-procedure.
9. Procedural details, including procedural and fluoroscopy times, will be collected for each subject. A matched cohort of patients who have undergone MB RFN (radiofrequency neurotomy) using the previous/current method have had the same data obtained for group comparisons.
Lumbar Paraspinal Mapping:
The adequate cauterization of the targeted medial branches will be confirmed using the paraspinal mapping (PM) technique of Haig. This testing will be carried out on all subjects at 3-6 weeks post radiofrequency neurotomies, by electromyographers blinded to the side and levels of the procedure. Subjects found to have reliable evidence of spontaneous electrical activity, as detailed in, will be deemed to have had a successful denervation of the medial branch in question.
Baseline PM will also be carried out at enrollment to document a normal baseline and to rule out the presence of spontaneous activity from other underlying pathology. Those found to have findings of spontaneous activity, upon baseline needle EMG of the lumbar paraspinals, will be excluded from the study.
Lumbar MRI - Post-Procedure
The ten study participants in this study will undergo lumbar MRI, using sequencing that will allow volume calculations of any soft tissue or bony findings of edema or coagulation. Experience thus far would indicate that the zone of edema can be identified, but that the zone of tissue coagulation (smaller than the zone of edema) cannot be reliably demarcated. Bench research using the Nimbus MEE probe indicates a zone of coagulation of 550 cubic mm or less, and the expected findings on MRI would consist of a zone of edema in this range, although MRI evidence of edema may be found in a larger volume of soft tissue, given that edema changes would be expected to be present in an area larger than the area of coagulation. The intention is to provide evidence that the area treated includes the known location of the targeted medial branch, but that bone edema or other unintended findings are not encountered. These MRIs will be obtained at 7 days post-procedure. If there is evidence for unintended bony edema, then these subjects will return for repeat MRI at 14 days post-procedure. If any of these unexpected findings are still present at 14 days post-procedure, then these subjects will be asked to undergo a third MRI at 6 weeks post-procedure. Images will be interpreted by a radiologist who is board certified in diagnostic radiology. Post-procedure MRI scoring will include documentation of the presence or absence of lesions, calculated volume of lesions, whether the lesion covers the anatomical location of the medial branch, and whether there is any evidence of bone edema at the lesion site(s).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lumbar MB RFN
Patients undergoing lumbar medial branch radiofrequency ablation using the Nimbus MEE Probe who undergo MRI and EMG validation testing of efficacy of intended lesion production.
Lumbar MB RFN
Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lumbar MB RFN
Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 or greater
* Appropriately selected patients using at least one set of diagnostic medial branch blocks
Exclusion Criteria
* Radicular pain or evidence of neurological compromise in the lower limbs (see clarification above - Target Population).
* Those unable to read English and complete the informed consent process
* Spondylolysis or lytic spondylolisthesis, degenerative spondylolisthesis which is Grade II+ or unstable.
* Systemic inflammatory, toxic, corticosteroid induced or congenital myopathy, or inflammatory arthritis
* Possible pregnancy or other reason that precludes the use of fluoroscopy, MRI, or EMG
* Significant lumbar scoliosis (Cobb angle \> 15 degrees).
* Radicular/neurological deficits or focal disc herniation and/or stenosis, with correlating radicular symptoms (defined as pain or paresthesias below the knee; pain reproduction with straight leg raising; leg \> back pain with extension/rotation maneuvers; radicular strength, reflex, or sensory changes consistent with their level of nerve root impingement).
* Immunologically suppressed, or has received steroids at any dose daily for \> 1 month within last 12 months
* Currently involved in another study or treatment that may affect the outcome of this study
* Evidence of spontaneous activity (denervation potentials) on baseline EMG
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nimbus Concepts, LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Denver Back Pain Specialists, LLC
Greenwood Village, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NimbusConcepts - LRFNV
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.